DEVELOPING SAFE AND EFFECTIVE IMMUNOTHERAPIES
Predictive tools that improve safety and efficacy of cancer treatment
Traditional cancer therapies are often accompanied by high toxicity and side effects. We are able to apply our proprietary methods to help design targeted immune therapies with superior response rates and safety profiles through harnessing the bodies own immune system. This approach holds a promise for developing truly safe cures for solid tumors. We develop our hypotheses and targets via data, but test these approach through our own lab work and experience in drug discovery to continuosly build, refine and hone our data and algorithms.
HIGH-ACCURACY PREDICTION OF CLINICAL RESPONSE
Javelin has developed a highly accurate predictive model for clinical response rates and safety. Predicting Overall Response Rate (ORR) to immuno-oncology treatments using our model shows high correlation (R2 = 99.8%) across multiple clinical trials. Using this model allows target development with improved tumor specificity.
Accurate predictive modeling
STRATIFICATION DRASTICALLY INCREASES TARGET EFFICACY
Javelin’s multidimensional platform enables full patient stratification that will dramatically improve response rate over single dimension (partial) stratification common to current practices.
DEVELOPING CAR-T THERAPIES WITH REPLICABLE HIGH SAFETY LEVELS ACROSS TARGETS
Javelin leverages its own multidimensional platform to develop CAR-T therapies that show superior tumor specificity and safety profiles compared to other CAR-T therapies in development. We have been able to replicate these results with multiple therapy programs
Learn more about how the Javelin Oncology platform integrates multidimensional data and sophisticated prediction methods to enhance identification, stratification and predictive capabilities around personalized immunotherapies
Learn how we use multidimensional data to inform target design
Using our proprietary models and algorithms to predict clinical response rates
Versatile platform shared with others to advance and accelerate their immuno-oncology applications